CN101048379A - 乐卡地平盐 - Google Patents

乐卡地平盐 Download PDF

Info

Publication number
CN101048379A
CN101048379A CNA2005800284676A CN200580028467A CN101048379A CN 101048379 A CN101048379 A CN 101048379A CN A2005800284676 A CNA2005800284676 A CN A2005800284676A CN 200580028467 A CN200580028467 A CN 200580028467A CN 101048379 A CN101048379 A CN 101048379A
Authority
CN
China
Prior art keywords
lercanidipine
salt
acid
crystalline
besylate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800284676A
Other languages
English (en)
Chinese (zh)
Inventor
A·莱奥纳蒂
G·莫塔
M·冯劳默
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Recordati Ireland Ltd
Original Assignee
Recordati Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recordati Ireland Ltd filed Critical Recordati Ireland Ltd
Publication of CN101048379A publication Critical patent/CN101048379A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
CNA2005800284676A 2004-08-24 2005-08-22 乐卡地平盐 Pending CN101048379A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60414904P 2004-08-24 2004-08-24
US60/604,149 2004-08-24

Publications (1)

Publication Number Publication Date
CN101048379A true CN101048379A (zh) 2007-10-03

Family

ID=35159792

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800284676A Pending CN101048379A (zh) 2004-08-24 2005-08-22 乐卡地平盐

Country Status (19)

Country Link
US (1) US7683179B2 (enExample)
EP (1) EP1799644B1 (enExample)
JP (1) JP2008510754A (enExample)
KR (1) KR20070045351A (enExample)
CN (1) CN101048379A (enExample)
AR (1) AR050467A1 (enExample)
AU (1) AU2005276619B2 (enExample)
BR (1) BRPI0514606A (enExample)
CA (1) CA2575078A1 (enExample)
EA (1) EA011773B1 (enExample)
ES (1) ES2462921T3 (enExample)
IL (1) IL180905A0 (enExample)
MX (1) MX2007002141A (enExample)
NO (1) NO20071515L (enExample)
NZ (1) NZ553127A (enExample)
PE (1) PE20060629A1 (enExample)
TW (1) TW200613275A (enExample)
WO (1) WO2006021397A1 (enExample)
ZA (1) ZA200702364B (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03007349A (es) * 2001-02-24 2003-12-04 Boehringer Ingelheim Pharma Derivados de xantina, su preparacion y su empleo como medicamentos.
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
AR053023A1 (es) * 2005-02-25 2007-04-18 Recordati Ireland Ltd Base libre de lercanidipina, metodos para su preparacion y composiciones farmaceuticas que las contienen
AR052918A1 (es) * 2005-02-25 2007-04-11 Recordati Ireland Ltd Clorhidrato de lercanidipina amorfo
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
SG174054A1 (en) 2006-05-04 2011-09-29 Boehringer Ingelheim Int Polymorphs
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
KR20090026282A (ko) 2006-06-12 2009-03-12 노파르티스 아게 Ｎ-히드록시-３-[４-[[[２-(２-메틸-1ｈ-인돌-３-일)에틸]아미노]메틸]페닐]-2ｅ-２-프로펜아미드의 염을 제조하는 방법
WO2008040367A1 (en) * 2006-08-01 2008-04-10 Union Quimico-Farmaceutica S.A. Lercanidipine hydrobromide, a process for its preparation, crystalline forms and compositions thereof
US20080175872A1 (en) * 2006-09-28 2008-07-24 Osmotica Corp. Controlled Release Dosage Form Containing Lercanidipine and a Performance-enhancing Acid
ES2306595B1 (es) * 2007-02-09 2009-09-11 Laboratorios Almirall S.A. Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
IN2009DN05509A (enExample) * 2007-03-14 2010-04-30 Teva Pharma
WO2009017813A1 (en) * 2007-08-02 2009-02-05 Teva Pharmaceutical Industries Ltd. O-desmethyl venlafaxine saccharinate
CA2706775A1 (en) 2007-11-26 2009-06-04 Teva Pharmaceutical Industries Ltd. Crystal forms of o-desmethylvenlafaxine fumarate
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
NZ591205A (en) 2008-08-01 2012-11-30 Medicines Co Pharmaceutical compositions comprising clevidipine and methods for producing low impurity concentrations of the same
HRP20200136T1 (hr) * 2008-08-01 2020-08-21 Chiesi Farmaceutici S.P.A. Farmaceutski pripravci i metode za njihovu stabilizaciju
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
RU2011113823A (ru) 2008-09-10 2012-10-20 БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) Комбинированная терапия, предназначенная для лечения диабета и связанных с ним состояний
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EP2382216A1 (en) 2008-12-23 2011-11-02 Boehringer Ingelheim International GmbH Salt forms of organic compound
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
EP3646859A1 (en) 2009-11-27 2020-05-06 Boehringer Ingelheim International GmbH Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
KR101409554B1 (ko) * 2010-03-29 2014-06-19 플리바 흐르바츠카 디.오.오. Ｏ-데스메틸벤라팍신 푸마레이트의 결정형
NZ602921A (en) 2010-05-05 2016-01-29 Boehringer Ingelheim Int Combination therapy comprising the administration of a glp-1 receptor agonist and a ddp-4 inhibitor
KR20230051307A (ko) 2010-06-24 2023-04-17 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
AU2012285904C1 (en) 2011-07-15 2017-08-31 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
EP4151218A1 (en) 2012-05-14 2023-03-22 Boehringer Ingelheim International GmbH Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
EP3110449B1 (en) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
EP3468562A1 (en) 2016-06-10 2019-04-17 Boehringer Ingelheim International GmbH Combinations of linagliptin and metformin
JPWO2023219106A1 (enExample) * 2022-05-10 2023-11-16

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8403866D0 (en) * 1984-02-14 1984-03-21 Recordati Chem Pharm Diphenylalkylaminoalkyl esters
IT1275532B (it) * 1995-07-14 1997-08-07 Recordati Chem Pharm Uso di derivati 1,4-diidropiridinici per la prevenzione e la terapia della degenerazione aterosclerotica della parete arteriosa
US5696139A (en) 1995-05-12 1997-12-09 Recordati S.A., Chemical And Pharmaceutical Company Use of S-enantiomers of 1,4-dihydropyridine derivatives for treating heart failure
US5912351A (en) 1995-05-12 1999-06-15 Recordati, S.A. Chemical And Pharmaceutical Company Anhydrous 1,4-Dihydropyridines and salts thereof
IT1301759B1 (it) * 1998-06-19 2000-07-07 Nicox Sa Sali nitrati di farmaci antiipertensivi
US20030069285A1 (en) 2001-08-06 2003-04-10 Recordati Ireland Limited Novel solvate and crystalline forms of lercanidipine hydrochloride
US6852737B2 (en) 2001-08-06 2005-02-08 Recordati Ireland Limited Crude and crystalline forms of lercanidipine hydrochloride
US6699892B2 (en) * 2002-06-04 2004-03-02 Yung Shin Pharmaceutical Industrial Co., Ltd. Pharmaceutically acceptable salt of amlodipine and method of preparing the same
EP1553941A1 (en) * 2002-10-16 2005-07-20 Recordati Ireland Limited Lisinopril/lercanidipine combination therapy
US20040198789A1 (en) * 2003-02-28 2004-10-07 Recordati Ireland Limited Lercanidipine/ARB/diuretic therapeutic combinations

Also Published As

Publication number Publication date
WO2006021397A1 (en) 2006-03-02
BRPI0514606A (pt) 2008-06-17
PE20060629A1 (es) 2006-08-11
EP1799644A1 (en) 2007-06-27
EP1799644B1 (en) 2014-02-12
JP2008510754A (ja) 2008-04-10
ES2462921T3 (es) 2014-05-26
IL180905A0 (en) 2007-07-04
AR050467A1 (es) 2006-10-25
NO20071515L (no) 2007-05-22
US7683179B2 (en) 2010-03-23
MX2007002141A (es) 2007-04-27
EA200700492A1 (ru) 2007-08-31
US20060047125A1 (en) 2006-03-02
AU2005276619B2 (en) 2009-04-30
KR20070045351A (ko) 2007-05-02
CA2575078A1 (en) 2006-03-02
WO2006021397A8 (en) 2006-04-27
ZA200702364B (en) 2008-09-25
EA011773B1 (ru) 2009-06-30
TW200613275A (en) 2006-05-01
NZ553127A (en) 2009-07-31
AU2005276619A1 (en) 2006-03-02

Similar Documents

Publication Publication Date Title
CN101048379A (zh) 乐卡地平盐
FI87785C (fi) Foerfarande foer framstaellning av farmaceutiskt aktivt, kristallint paroxetinhydrokloridhemihydrat
CN1907967A (zh) 抗组胺哌啶衍生物,其多晶形物和假同晶物的无水和水合物形式的制备方法
CN1845917A (zh) 3－[(2－{[4－(已氧基羰基氨基－亚氨基－甲基)－苯氨基]－甲基}－1－甲基－1 h－苯并咪唑－5－羰基)－吡啶－2－基－氨基]－丙酸乙酯－甲磺酸酯及其作为药物的用途
NO335651B1 (no) Nye krystallinske polymorfe former av lerkanidipinhydroklorid og fremgangsmåte for fremstilling derav
WO2014008794A1 (zh) 一种酪氨酸激酶抑制剂的二马来酸盐的i型结晶及制备方法
US20030083355A1 (en) Novel crude and crystalline forms of lercanidipine hydrochloride
US10870654B2 (en) Pharmaceutically acceptable salts and polymorphic forms of hydrocodone benzoic acid enol ester and processes for making same
CN1148382A (zh) 用于光学拆分外消旋α-[4-(1，1-二甲基乙基)苯基]-4-(羟基二苯基甲基)-1-哌啶丁醇和其衍生化合物的方法和非对映体盐
RU2269516C2 (ru) НОВЫЕ КРИСТАЛЛИЧЕСКИЕ ФОРМЫ 4-[4-[4-(ГИДРОКСИДИФЕНИЛМЕТИЛ)-1-ПИПЕРИДИНИЛ]-1-ГИДРОКСИБУТИЛ]-α, α-ДИМЕТИЛБЕНЗОЛУКСУСНОЙ КИСЛОТЫ И ЕЕ ГИДРОХЛОРИДА И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
CN1114592C (zh) 奥沙奈丹的晶型
CN101052393A (zh) 氮杂双环己烷的新型多晶型物
CN1720228A (zh) 制备利培酮及其中间体的方法
JP2005502648A (ja) 塩酸レルカニジピンの溶媒和物及び塩酸レルカニジピンの新しい結晶性形状
JP5952748B2 (ja) フタロイルアムロジピンの新規結晶形態およびそれを用いる高純度なアムロジピンベシル酸塩の製造方法
KR20090044694A (ko) 모사프리드의 신규한 동질이상체 및 유사동질이상체
CN101675039A (zh) 邻苯二甲酰基氨氯地平的丙酮溶剂化物
KR100713136B1 (ko) 무수 레르카니디핀 염화수소 결정다형의 개선된 신규결정화 방법
JP2012500268A (ja) ７−クロロ−Ｎ，Ｎ，５−トリメチル−４−オキソ−３−フェニル−３，５−ジヒドロ−４Ｈ−ピリダジノ［４，５−ｂ］インドール−１−アセトアミドの多形体を製造するための方法
CN1809358A (zh) 卡麦角林的多晶型物
HK1077301A (en) Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudormophs thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20071003